Deza G, et al. - In a cohort of real-life plaque psoriasis patients, researchers assessed the effectiveness and safety of ixekizumab. They retrospectively reviewed the charts of 100 patients with moderate to severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centers. Clinical variables like body mass index, disease duration, or the presence of psoriatic arthritis did not affect ixekizumab response. Nonetheless, at week 12-16, significantly higher PASI 75 response rate was demonstrated by the bio-naive group vs patients previously exposed to biologic agents. The usefulness and safety of initial experience with ixekizumab in the treatment of plaque psoriasis patients was confirmed in the findings.